TP53 and ovarian cancer: APR-246, a prodrug that binds to cysteine residues in mutant p53 and restores its wild-type function, showed synergistic effects with chemotherapy in ovarian cancer cell lines and resensitized platinum-resistant ovarian cancer cells [73].